Establishment of AdriamycinResistance Cell Substrain SMMC7721/Adriamycin of Human Hepatocellular Carcinoma and Research of Its Characteristics_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHI Xing ¹ , YAN Lnan ¹ , LIN Ping ² , LIN Qiyuan ¹

Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

Keywords：

Multidrug resistanceCell substrain/EstablishmentHepatocellular carcinomaChemotherapy

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo establish multidrugresistance cell substrain of human hepatocellular carcinoma and to investigate its characteristics.MethodsSMMC7721 cell strain was cultured in Adriamycin(ADM). The multidrugresistance cell substrain SMMC7721/ADM was harvested after a long period of culture by gradually increasing the concentration of ADM and its characteristics were investigated. Results①The drug resistance of SMMC7721/ADM to ADM increased by 33.3 times, to Vincristine 16.8 times, to Diamminedichloroplatinum 2.8 times. ②The drug resistance cell substrain had almost the same growth velocity as its parental generation. The doubling time was 32.0 hours and 30.5 hours respectively. They had the analogous growth curves. ③The obvious difference between the drug resistance cell substrain and its parental generation was that the former’s microvilli became thick, short and scattered by scanning and transmitting electron microscopy. ④The multidrug resistance cell substrain kept the characteristics of hepatocellular carcinoma, it could be transplanted into the subcutaneous tissue of nude mice. ⑤The drug resistance of the cell substrain reduced to 28.0% and 9.2%after removal of the drug for 1 month and 2 months respectively, its drug resistance could remain stable (35.4 times) after 2 months of culture in ADM (0.04 μg/ml).ConclusionThe SMMC7721/ADM cell substrain has the stable fundamental characteristics of a drug resistance cell strain.

Citation： ZHI Xing,YAN Lnan,LIN Ping,LIN Qiyuan. Establishment of AdriamycinResistance Cell Substrain SMMC7721/Adriamycin of Human Hepatocellular Carcinoma and Research of Its Characteristics. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(3): 219-221. doi: Copy

1.	Shiraga K, Sakaguchi K, Senoh T, et al. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicinresistant sublines [Ｊ]. J Gastroenterol Hepatol, 2001; 16(4)∶460.
2.	程国钧, 李亚里, 田方，等. 不同方式诱导人卵巢癌顺铂耐药细胞株的比较 [Ｊ]. 中华肿瘤杂志, 2001; 23（4）∶305.
3.	陆家齐, 陆连荣, 蒋彦和, 等. PdGC81 人体胃底分化腺癌细胞系的建立及其生物学特征的观察 [Ｊ]. 中华肿瘤杂志, 1986； 8（1）∶4.
4.	赵宪琪. 乳腺癌细胞系的建立与应用研究 [Ｊ]. 实用肿瘤学杂志, 2001; 15（3）∶239.
5.	Chauffert B, Martin M, Hammann A, et al. Amiodaroneinduced enhancement of doxorubicin and 4’deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo [Ｊ]. Cancer Res, 1986; 46(2)∶825.
6.	Twentyman PR, Fox NE, Wright KA, et al. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells [Ｊ]. Br J Cancer, 1986; 53(4)∶529.
7.	梁永锯，周肵熙，潘启超，等. 肝癌体外药敏感性试验 [Ｊ]. 肿瘤, 2001; 21（1）∶17.
8.	Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein [Ｊ]. Am J Pathol, 1996; 148(4)∶1237.
9.	McGovern F, Kachel T, Vijan S, et al. Establishment and characterization of a doxorubicinresistant human bladder cancer cell line (MGHU1R) [Ｊ]. J Urol, 1988; 140(2)∶410.
10.	Keizer HG, Schuurhuis GJ, Broxterman HJ, et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased Pglycoprotein expression in cultured SW1573 human lung tumor cells [Ｊ]. Cancer Res, 1989; 49(11)∶2988.
11.	Kaye SB. The multidrug resistance phenotype [Ｊ]. Br J Cancer, 1988; 58(6)∶691.
12.	Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line MESSA [Ｊ]. Cancer Res, 1985; 45(9)∶4091.

1. Shiraga K, Sakaguchi K, Senoh T, et al. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicinresistant sublines [Ｊ]. J Gastroenterol Hepatol, 2001; 16(4)∶460.
2. 程国钧, 李亚里, 田方，等. 不同方式诱导人卵巢癌顺铂耐药细胞株的比较 [Ｊ]. 中华肿瘤杂志, 2001; 23（4）∶305.
3. 陆家齐, 陆连荣, 蒋彦和, 等. PdGC81 人体胃底分化腺癌细胞系的建立及其生物学特征的观察 [Ｊ]. 中华肿瘤杂志, 1986； 8（1）∶4.
4. 赵宪琪. 乳腺癌细胞系的建立与应用研究 [Ｊ]. 实用肿瘤学杂志, 2001; 15（3）∶239.
5. Chauffert B, Martin M, Hammann A, et al. Amiodaroneinduced enhancement of doxorubicin and 4’deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo [Ｊ]. Cancer Res, 1986; 46(2)∶825.
6. Twentyman PR, Fox NE, Wright KA, et al. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells [Ｊ]. Br J Cancer, 1986; 53(4)∶529.
7. 梁永锯，周肵熙，潘启超，等. 肝癌体外药敏感性试验 [Ｊ]. 肿瘤, 2001; 21（1）∶17.
8. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein [Ｊ]. Am J Pathol, 1996; 148(4)∶1237.
9. McGovern F, Kachel T, Vijan S, et al. Establishment and characterization of a doxorubicinresistant human bladder cancer cell line (MGHU1R) [Ｊ]. J Urol, 1988; 140(2)∶410.
10. Keizer HG, Schuurhuis GJ, Broxterman HJ, et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased Pglycoprotein expression in cultured SW1573 human lung tumor cells [Ｊ]. Cancer Res, 1989; 49(11)∶2988.
11. Kaye SB. The multidrug resistance phenotype [Ｊ]. Br J Cancer, 1988; 58(6)∶691.
12. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicinselected variants of the human sarcoma cell line MESSA [Ｊ]. Cancer Res, 1985; 45(9)∶4091.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Establishment of AdriamycinResistance Cell Substrain SMMC7721/Adriamycin of Human Hepatocellular Carcinoma and Research of Its Characteristics

Abstract Full text Figures/Tables Video References Cited by

Format

Content